Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 32

Sort by

Sort Order Select

Journal Articles

Birtamimab plus standard of care in light-chain amyloidosis: the phase 3 randomized placebo-controlled VITAL trial

Morie A. Gertz, Adam D. Cohen, Raymond L. Comenzo, Efstathios Kastritis, Heather J. Landau, Edward N. Libby, Michaela Liedtke, Vaishali Sanchorawala, Stefan Schönland, Ashutosh Wechalekar, Jeffrey A. Zonder, Giovanni Palladini, Jackie Walling, Spencer Guthrie, Christie Nie, Carol Karp, Yuying Jin, Gene G. Kinney, Giampaolo Merlini

Blood (2023) 142 (14): 1208–1218.

https://doi.org/10.1182/blood.2022019406

Published: 2023

Includes: Supplemental data

Journal Articles

A Randomized Phase III Trial of Melphalan and Dexamethasone (MDex) Versus Bortezomib, Melphalan and Dexamethasone (BMDex) for Untreated Patients with AL Amyloidosis

Blood (2016) 128 (22): 646.

https://doi.org/10.1182/blood.V128.22.646.646

Published: 2016

Journal Articles

Challenges of Using NT-Probnp for Response Assessment in Systemic AL Amyloidosis - Analysis of a Prospective Study

Ashutosh Wechalekar, MD FRCPath, Darren Foard, Carol Whelan, MD FRCP, Mariana Fontana, Thirusha Lane, RN MSc, Candida Quarta, Shameem Mahmood, FRCPath, Helen Lachmann, MD FRCP, Julian D Gillmore, MD PhD FRCP, Philip N Hawkins, MD PhD FMedSci

Blood (2016) 128 (22): 4511.

https://doi.org/10.1182/blood.V128.22.4511.4511

Published: 2016

Journal Articles

Treatment recommendations from the Eighth International Workshop on Waldenström’s Macroglobulinemia

Véronique Leblond, Efstathios Kastritis, Ranjana Advani, Stephen M. Ansell, Christian Buske, Jorge J. Castillo, Ramón García-Sanz, Morie Gertz, Eva Kimby, Charalampia Kyriakou, Giampaolo Merlini, Monique C. Minnema, Pierre Morel, Enrica Morra, Mathias Rummel, Ashutosh Wechalekar, Christopher J. Patterson, Steven P. Treon, Meletios A. Dimopoulos

Blood (2016) 128 (10): 1321–1328.

https://doi.org/10.1182/blood-2016-04-711234

Published: 2016

Journal Articles

Is Treatment with Bortezomib for Multiple Myeloma or Amyloidosis Associated with Cytomegalovirus Reactivation?

Isobel Ramsay, Dunnya De-silva, Sarah Worthington, Mark Coyne, Ashutosh Wechalekar, Paul D Griffiths

Blood (2015) 126 (23): 4259.

https://doi.org/10.1182/blood.V126.23.4259.4259

Published: 2015

Journal Articles

Oral Doxycycline Improves Outcomes of Stage III AL Amyloidosis - a Matched Case Control Study

Ashutosh Wechalekar, MD FRCPath, Carol Whelan, MDFRCP, Helen Lachmann, MDFRCP, Marianna Fontana, MD, Shameem Mahmood, FRCPath, Julian D Gillmore, MDPhDFRCP, Philip N Hawkins, MDPhDFMedSci

Blood (2015) 126 (23): 732.

https://doi.org/10.1182/blood.V126.23.732.732

Published: 2015

Journal Articles

Cancer-Selective Targeting of the NF-κB Survival Pathway in Multiple Myeloma with the GADD45β/MKK7 Inhibitor, DTP3

Blood (2015) 126 (23): 868.

https://doi.org/10.1182/blood.V126.23.868.868

Published: 2015

Journal Articles

Dose-Dependent Progressive Immunotherapeutic Clearance of Systemic Amyloid Deposits By Repeated Doses of Antibody to Serum Amyloid P Component (SAP)

Mark B Pepys, MDPhDFRS FMedSci, Louise M Cookson, BSc, Sharon V Barton, BSc MSc, Alienor C Berges, PharmD, Thirusha Lane, RN MSc, David Hutt, BAppSc, Marianna Fontana, MD, James C Moon, MD, Julian D Gillmore, MDPhDFRCP, Ashutosh Wechalekar, MDFRCPath FRCP, Philip N Hawkins, MDPhDFMedSci, Duncan B Richards, DM FRCP

Blood (2015) 126 (23): 1836.

https://doi.org/10.1182/blood.V126.23.1836.1836

Published: 2015

Journal Articles

A Prospective Study of Treatment Outcomes in 179 Patients with Advanced Cardiac Stage STAGE IIIb Amyloidosis

Belen Sevillano, Haematology Specialist, Ashutosh Wechalekar, MDFRCPath FRCP, Darren Foard, Specialist Nurse, Carol Whelan, MDFRCP, Marianna Fontana, MD, Cristina Quarta, Shameem Mahmood, FRCPath, Helen Lachmann, MDFRCP, Julian D Gillmore, MDPhDFRCP, Philip N Hawkins, MDPhDFMedSci

Blood (2015) 126 (23): 5357.

https://doi.org/10.1182/blood.V126.23.5357.5357

Published: 2015

Journal Articles

A Matched Case Control Study of Doxycycline Added to Chemotherapy for Reducing Early Mortality in Patients with Advanced Cardiac AL Amyloidosis from the Alchemy Study Cohort

Ashutosh Wechalekar, MD FRCPath, Carol Whelan, MD, Sajitha Sachchithanantham, MRCP, FRCPath, Marianna Fontana, MD, Shameem Mahmood, MRCP. FRCPath, Darren Foard, RN, Thirusha Lane, RN, Helen J Lachmann, MD FRCP, Julian D Gillmore, MD FRCP, Philip N Hawkins, MD FRCP, FMedSci

Blood (2014) 124 (21): 3485.

https://doi.org/10.1182/blood.V124.21.3485.3485

Published: 2014

Journal Articles

Exome Sequencing to Define a Genetic Signature of Plasma Cells in Systemic AL Amyloidosis

Eileen M Boyle, MD, Brian A Walker, PhD, Dorota Rowczienio, MSc, Christopher P Wardell, PhD, Alexander Murison, PhD, Aneta Mikulasova, M.Sc., Sajitha Sachchithanantham, BSc,MBBS,MRCP,FRCPath,, Anna Baginska, Shameem Mahmood, MRCP. FRCPath, Julian D Gillmore, Helen J Lachmann, MD FRCP, Philip N Hawkins, MD FRCP, FMedSci, Xavier Leleu, MD PhD, Faith E Davies, MD, Gareth J. Morgan, MD PhD, Ashutosh Wechalekar, MDFRCPath

Blood (2014) 124 (21): 726.

https://doi.org/10.1182/blood.V124.21.726.726

Published: 2014

Journal Articles

Does Electrocardiogram Offer an Alternative to Radiological Imaging in the Confirmation of Tip Positioning for the Insertion of Peripherally Inserted Central Catheters; A Comparison of 120 Patients

Sasha D Brimacombe, Bsc (Hons) Cancer Care, Lisa McMonagle, BSc Adult Nursing, Ashutosh Wechalekar, Dr, Christopher J McNamara

Blood (2014) 124 (21): 1314.

https://doi.org/10.1182/blood.V124.21.1314.1314

Published: 2014

Journal Articles

The Prognostic Significance of Phenotypically ‘Normal’ Plasma Cells in Chemotherapy Treated AL Patients with Underlying MGUS and Multiple Myeloma

Sajitha Sachchithanantham, BSc,MBBS,MRCP,FRCPath,, Ruth M de Tute, Anna Baginska, Christopher Parrish, MD, Shameem Mahmood, MRCP. FRCPath, Andy Rawstron, PhD, Julian D Gillmore, MD FRCP, Helen J Lachmann, MD FRCP, Philip N Hawkins, Roger G Owen, MD, Ashutosh Wechalekar, Dr

Blood (2014) 124 (21): 2073.

https://doi.org/10.1182/blood.V124.21.2073.2073

Published: 2014

Journal Articles

Biweekly Bortezomib Is More Efficacious Than Weekly Bortezomib When Used As First Line In Patients With Systemic AL Amyloidosis

Sajitha Sachchithanantham, MRCP, FRCPath, Shameem Mahmood, MRCP. FRCPath, Rabya Sayed, MRCP, Ketna Patel, MRCP, Marianna Fontana, MD, Thirusha Lane, RN, Lisa Rannigan, RN, Darren Foard, RN, Carol Whelan, MD, Helen Lachmann, MD, Julian D Gillmore, MD, Philip N Hawkins, MD, Ashutosh Wechalekar, MD, FRCPath

Blood (2013) 122 (21): 1981.

https://doi.org/10.1182/blood.V122.21.1981.1981

Published: 2013

Journal Articles

Use Of Plasma Cell Immunophenotype As Prognostic Markers In Patients With Systemic AL Amyloidosis

Sajitha Sachchithanantham, MRCP, FRCPath, Anna Baginska, Dorota Rowczenio, Shameem Mahmood, MRCP, FRCPath, Rabya Sayed, MRCP, Ketna Patel, MRCP, Thirusha Lane, RN, Lisa Rannigan, RN, Darren Foard, RN, Carol Whelan, MD, Helen Lachmann, MD, Julian D Gillmore, MD, Philip N Hawkins, MD, Ashutosh Wechalekar, MD FRCPath

Blood (2013) 122 (21): 3120.

https://doi.org/10.1182/blood.V122.21.3120.3120

Published: 2013

Journal Articles

Risk Of Progression Of Localised Amyloidosis To Systemic Disease In 606 Patients Over 30 Years

Shameem Mahmood, MRCP. FRCPath, Sajitha Sachchithanantham, MRCP. FRCPath, Frank Bridoux, Thirusha Lane, RN, Lisa Rannigan, RN, Darren Foard, RN, Rabya Sayed, MRCP, Ketna Patel, MRCP, Marianna Fontanna, MD, Carol Whelan, MD, Helen J Lachmann, MD, FRCP, Julian D Gillmore, MD, Philip N Hawkins, MD, Ashutosh Wechalekar, MD FRCPath

Blood (2013) 122 (21): 3143.

https://doi.org/10.1182/blood.V122.21.3143.3143

Published: 2013

Journal Articles

Exome Sequencing To Define A Genetic Signature Of Plasma Cells In Systemic AL Amyloidosis

Brian A Walker, PhD, Dorota Rowczienio, MSc, Eileen M Boyle, MD, Christopher P Wardell, PhD, Sajitha Sachchithanantham, MRCP, FRCPath, Anna Baginska, Julian D Gillmore, MD, Shameem Mahmood, MRCP. FRCPath, Helen J Lachmann, MD, FRCP, Philip N Hawkins, Faith E Davies, MD, Gareth J Morgan, MD PhD, Ashutosh Wechalekar, MD, FRCPath

Blood (2013) 122 (21): 3098.

https://doi.org/10.1182/blood.V122.21.3098.3098

Published: 2013

Journal Articles

A Matched Comparison of Cyclophosphamide, Bortezomib and Dexamethasone (CVD) Versus Cyclophosphamide, Thalidomide and Dexamethasone (CTD) in the Treatment of Mayo Cardiac Stage III Patients with AL Amyloidosis.

Christopher P Venner, MD, Thirusha Lane, RN, Darren Foard, RN, Lisa Rannigan, RN, Shameem Mahmood, MBBCh. FRCPath, Simon DJ Gibbs, Jennifer Pinney, MD, Sanjay Banypersad, MD, Jason Dungu, Carol Whelan, Helen Lachmann, MD, Julian D Gillmore, MD, Philip N Hawkins, MD, Ashutosh Wechalekar, MD

Blood (2012) 120 (21): 2966.

https://doi.org/10.1182/blood.V120.21.2966.2966

Published: 2012

Journal Articles

Treatment and Outcome of 267 Patients with IgM-Related AL Amyloidosis

Murielle Roussel, MD, Giovanni Palladini, Simon DJ Gibbs, Christopher P. Venner, MD, Jean-Paul Fermand, Helen J Lachmann, MD, FRCP, Julian D Gillmore, MD, Philip N Hawkins, MD, Giampaolo Merlini, Arnaud Jaccard, Ashutosh Wechalekar, MD

Blood (2012) 120 (21): 4074.

https://doi.org/10.1182/blood.V120.21.4074.4074

Published: 2012

Journal Articles

Continuous Therapy with Lenalidomide Correlates with Improved Progression Free Survival in Heavily Pre-Treated Patients with AL Amyloidosis.

Shameem Mahmood, MBBCh. FRCPath, Christopher P. Venner, MD, Thirusha Lane, RN, Lisa Rannigan, RN, Darren Foard, RN, Jennifer Pinney, MD, Sanjay Banypersad, MD, Jason Dungu, Carol Whelan, Helen J Lachmann, MD, FRCP, Julian D Gillmore, MD, Philip N Hawkins, MD, Ashutosh Wechalekar, MD, FRCPath

Blood (2012) 120 (21): 2978.

https://doi.org/10.1182/blood.V120.21.2978.2978

Published: 2012

NARROW

Birtamimab plus standard of care in light-chain amyloidosis: the phase 3 randomized placebo-controlled VITAL trial

A Randomized Phase III Trial of Melphalan and Dexamethasone (MDex) Versus Bortezomib, Melphalan and Dexamethasone (BMDex) for Untreated Patients with AL Amyloidosis

Challenges of Using NT-Probnp for Response Assessment in Systemic AL Amyloidosis - Analysis of a Prospective Study

Treatment recommendations from the Eighth International Workshop on Waldenström’s Macroglobulinemia

Is Treatment with Bortezomib for Multiple Myeloma or Amyloidosis Associated with Cytomegalovirus Reactivation?

Oral Doxycycline Improves Outcomes of Stage III AL Amyloidosis - a Matched Case Control Study

Cancer-Selective Targeting of the NF-κB Survival Pathway in Multiple Myeloma with the GADD45β/MKK7 Inhibitor, DTP3

Dose-Dependent Progressive Immunotherapeutic Clearance of Systemic Amyloid Deposits By Repeated Doses of Antibody to Serum Amyloid P Component (SAP)

A Prospective Study of Treatment Outcomes in 179 Patients with Advanced Cardiac Stage STAGE IIIb Amyloidosis

A Matched Case Control Study of Doxycycline Added to Chemotherapy for Reducing Early Mortality in Patients with Advanced Cardiac AL Amyloidosis from the Alchemy Study Cohort

Exome Sequencing to Define a Genetic Signature of Plasma Cells in Systemic AL Amyloidosis

Does Electrocardiogram Offer an Alternative to Radiological Imaging in the Confirmation of Tip Positioning for the Insertion of Peripherally Inserted Central Catheters; A Comparison of 120 Patients

The Prognostic Significance of Phenotypically ‘Normal’ Plasma Cells in Chemotherapy Treated AL Patients with Underlying MGUS and Multiple Myeloma

Biweekly Bortezomib Is More Efficacious Than Weekly Bortezomib When Used As First Line In Patients With Systemic AL Amyloidosis

Use Of Plasma Cell Immunophenotype As Prognostic Markers In Patients With Systemic AL Amyloidosis

Risk Of Progression Of Localised Amyloidosis To Systemic Disease In 606 Patients Over 30 Years

Exome Sequencing To Define A Genetic Signature Of Plasma Cells In Systemic AL Amyloidosis

A Matched Comparison of Cyclophosphamide, Bortezomib and Dexamethasone (CVD) Versus Cyclophosphamide, Thalidomide and Dexamethasone (CTD) in the Treatment of Mayo Cardiac Stage III Patients with AL Amyloidosis.

Treatment and Outcome of 267 Patients with IgM-Related AL Amyloidosis

Continuous Therapy with Lenalidomide Correlates with Improved Progression Free Survival in Heavily Pre-Treated Patients with AL Amyloidosis.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only